Chugai plans KRW 3 billion South Korea subsidiary: stock after-hours at EUR 34.56, plus 0.88 percent
Published on 10/07/2026 at 20:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Chugai Pharmaceutical decided on September 30, 2026, to establish a South Korean subsidiary with planned capital of KRW 3 billion. At 8:38 p.m. CEST on October 7, 2026, Chugai stock was EUR 34.56 after-hours at Lang & Schwarz, up 0.88 percent versus the EUR 34.26 prior close on October 6. The company’s Tokyo Stock Exchange code is 4519, according to the Chugai Pharmaceutical release.
October 7 trading
Lang & Schwarz showed a bid of EUR 34.32 and an ask of EUR 34.80 alongside the after-hours price. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.
South Korea expansion
Chugai Pharma Korea is scheduled to be incorporated on November 2, 2026. The wholly owned subsidiary is intended to obtain marketing authorizations, import and sell pharmaceutical products, and build an in-house sales structure in South Korea. Chugai said the company will expand its functions and workforce in phases ahead of future product launches. The subsidiary is planned as Chugai’s core base in the country, where the company has previously relied primarily on out-licensing to local partners, according to the company’s September 30 release.
Development update
In a separate September 28 announcement, Chugai said development of emugrobart, also known as GYM329, for obesity would be discontinued and that rights previously licensed to Roche would return to Chugai. Chugai said it had begun preparing to resume development for spinal muscular atrophy while considering potential out-licensing opportunities. The company said the announcement was not expected to affect its consolidated financial forecast for the year ending December 2026, according to the company’s notice.
